Literature DB >> 19838705

EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

Andrea Varrone1, Susanne Asenbaum, Thierry Vander Borght, Jan Booij, Flavio Nobili, Kjell Någren, Jacques Darcourt, Ozlem L Kapucu, Klaus Tatsch, Peter Bartenstein, Koen Van Laere.   

Abstract

These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting the results of fluorine-18 fluoro-2-deoxyglucose ([(18)F]FDG) PET imaging of the brain. The aim is to help achieve a high standard of FDG imaging, which will increase the diagnostic impact of this technique in neurological and psychiatric practice. The present document replaces a former version of the guidelines that were published in 2002 [1] and includes an update in the light of advances in PET technology, the introduction of hybrid PET/CT systems and the broadening clinical indications for FDG brain imaging. These guidelines are intended to present information specifically adapted for European practice. The information provided should be taken in the context of local conditions and regulations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19838705     DOI: 10.1007/s00259-009-1264-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Metabolic correlates of levodopa response in Parkinson's disease.

Authors:  A Feigin; M Fukuda; V Dhawan; S Przedborski; V Jackson-Lewis; M J Mentis; J R Moeller; D Eidelberg
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

2.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

Review 3.  [Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference].

Authors:  T Kuwert; P Bartenstein; F Grünwald; K Herholz; R Larisch; O Sabri; H J Biersack; E Moser; H W Müller-Gärtner; O Schober; M Schwaiger; U Büll; W D Heiss
Journal:  Nervenarzt       Date:  1998-12       Impact factor: 1.214

4.  Ethical clinical practice of functional brain imaging. Society of Nuclear Medicine Brain Imaging Council.

Authors: 
Journal:  J Nucl Med       Date:  1996-07       Impact factor: 10.057

5.  Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET.

Authors:  G Berding; P Odin; D J Brooks; G Nikkhah; C Matthies; T Peschel; M Shing; H Kolbe; J van Den Hoff; H Fricke; R Dengler; M Samii; W H Knapp
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

6.  FDG PET in the differential diagnosis of parkinsonian disorders.

Authors:  Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg
Journal:  Neuroimage       Date:  2005-04-26       Impact factor: 6.556

7.  Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure.

Authors:  G Lucignani; K C Schmidt; R M Moresco; G Striano; F Colombo; L Sokoloff; F Fazio
Journal:  J Nucl Med       Date:  1993-03       Impact factor: 10.057

8.  No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans.

Authors:  S G Hasselbalch; G M Knudsen; C Videbaek; L H Pinborg; J F Schmidt; S Holm; O B Paulson
Journal:  Diabetes       Date:  1999-10       Impact factor: 9.461

9.  Clinical evaluation of interictal fluorine-18-fluorodeoxyglucose PET in partial epilepsy.

Authors:  T R Henry; J Engel; J C Mazziotta
Journal:  J Nucl Med       Date:  1993-11       Impact factor: 10.057

10.  Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner.

Authors:  Tung-Hsin Wu; Yung-Hui Huang; Jason J S Lee; Shih-Yuan Wang; Su-Cheng Wang; Cheng-Tau Su; Liang-Kung Chen; Tieh-Chi Chu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-08       Impact factor: 9.236

View more
  147 in total

Review 1.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

Review 2.  Neural circuit modulation during deep brain stimulation at the subthalamic nucleus for Parkinson's disease: what have we learned from neuroimaging studies?

Authors:  Daniel L Albaugh; Yen-Yu Ian Shih
Journal:  Brain Connect       Date:  2013-12-18

3.  Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.

Authors:  Frederic Sampedro; Saul Martínez-Horta; Jesús Perez-Perez; Andrea Horta-Barba; Diego Alfonso Lopez-Mora; Valle Camacho; Alejandro Fernández-León; Beatriz Gomez-Anson; Ignasi Carrió; Jaime Kulisevsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

4.  Effect of hyperglycemia on brain and liver 18F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging.

Authors:  Benjamin L Viglianti; Ka Kit Wong; Stephanie M Wimer; Aishwarya Parameswaran; Bin Nan; Christy Ky; Danyelle M Townsend; Domenico Rubello; Kirk A Frey; Milton D Gross
Journal:  Biomed Pharmacother       Date:  2017-02-07       Impact factor: 6.529

Review 5.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

6.  Vulnerability of multiple large-scale brain networks in dementia with Lewy bodies.

Authors:  Arianna Sala; Silvia Paola Caminiti; Leonardo Iaccarino; Luca Beretta; Sandro Iannaccone; Giuseppe Magnani; Alessandro Padovani; Luigi Ferini-Strambi; Daniela Perani
Journal:  Hum Brain Mapp       Date:  2019-07-19       Impact factor: 5.038

7.  18F-fluoro-2-deoxy-d-glucose (FDG) uptake. What are we looking at?

Authors:  Gianmario Sambuceti; Vanessa Cossu; Matteo Bauckneht; Silvia Morbelli; AnnaMaria Orengo; Sonia Carta; Silvia Ravera; Silvia Bruno; Cecilia Marini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05       Impact factor: 9.236

8.  The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.

Authors:  Silvia Morbelli; Javier Arbizu; Jan Booij; Ming-Kai Chen; Gael Chetelat; Donna J Cross; Mehdi Djekidel; Alexander Drzezga; Ozgul Ekmekcioglu; Valentina Garibotto; Swen Hesse; Kazunari Ishii; Lida Jafari; Adriaan A Lammertsma; Ian Law; Dana Mathews; Satoshi Minoshima; Karina Mosci; Marco Pagani; Sabina Pappata; Daniel Hillel Silverman; Alberto Signore; Elsmarieke Van De Giessen; Victor Villemagne; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-06       Impact factor: 9.236

9.  Gender differences in healthy aging and Alzheimer's Dementia: A 18 F-FDG-PET study of brain and cognitive reserve.

Authors:  Maura Malpetti; Tommaso Ballarini; Luca Presotto; Valentina Garibotto; Marco Tettamanti; Daniela Perani
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

10.  Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.

Authors:  Claudio Liguori; Agostino Chiaravalloti; Marzia Nuccetelli; Francesca Izzi; Giuseppe Sancesario; Andrea Cimini; Sergio Bernardini; Orazio Schillaci; Nicola Biagio Mercuri; Placidi Fabio
Journal:  J Neurol       Date:  2017-09-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.